The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting
Open accessPublished version of a preprint
Abstract
Background: Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirmed cases in Qatar. Methods: All SARS-CoV-2 laboratory-confirmed cases with at least 1 polymerase chain reaction–positive swab that was ≥45 days after a first positive swab were individually investigated for evidence of reinfection. Viral genome sequencing of the paired first positive and reinfection viral specimens was conducted to confirm reinfection. Results: Out of 133 266 laboratory-confirmed SARS-CoV-2 cases, 243 persons (0.18%) had at least 1 subsequent positive swab ≥45 days after the first positive swab. Of these, 54 cases (22.2%) had strong or good evidence for reinfection. Median time between the first swab and reinfection swab was 64.5 days (range, 45–129). Twenty-three of the 54 cases (42.6%) were diagnosed at a health facility, suggesting presence of symptoms, while 31 (57.4%) were identified incidentally through random testing campaigns/surveys or contact tracing. Only 1 person was hospitalized at the time of reinfection but was discharged the next day. No deaths were recorded. Viral genome sequencing confirmed 4 reinfections of 12 cases with available genetic evidence. Reinfection risk was estimated at 0.02% (95% confidence interval [CI], .01%–.02%), and reinfection incidence rate was 0.36 (95% CI, .28–.47) per 10 000 person-weeks. Conclusions: SARS-CoV-2 reinfection can occur but is a rare phenomenon suggestive of protective immunity against reinfection that lasts for at least a few months post primary infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281 · cited 1×
“13 Meanwhile, for two pairs, there was conclusive evidence for reinfection with multiple changes of allele frequency and presence of the D614G mutation (23403bp A>G)—a variant that appeared and expanded replacing the original D614 form [21, 22].”
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · cited 1×
“The intensity of the epidemic with a high risk of re-exposure to the infection, as well as the availability of a centralized data-capture system of all laboratory-confirmed infections, provided an opportunity to epidemiologically assess the presence and incidence of reinfections; a poorly-understood feature of SARS-Co…”
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
To, K. K.-W., Hung, I. F.-N., Ip, J. D., Chu, A. W.-H., Chan, W.-M., Tam, A. R., Fong, C. H.-Y., Yuan, S., Tsoi, H.-W., Ng, A. C.-K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1275 · Cited by 746
Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., Butt, A. A., Coyle, P., Jeremijenko, A., Kaleeckal, A. H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85428-7 · Cited by 148
Self-citationEpidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses
Makhoul, M., Ayoub, H. H., Chemaitelly, H., Seedat, S., Mumtaz, G. R., Al-Omari, S., & Abu-Raddad, L. J. (2020) · Vaccines · doi:10.3390/vaccines8040668 · Cited by 107
Self-citationJeremijenko, A., Chemaitelly, H., Ayoub, H. H., Alishaq, M., Abou-Samra, A.-B., Al Ajmi, J. A. A. A., Al Ansari, N. A. A., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., et al. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2705.204365 · Cited by 97
Self-citationAyoub, H. H., Chemaitelly, H., Seedat, S., Makhoul, M., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., Butt, A. A., Coyle, P., Jeremijenko, A., et al. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05005 · Cited by 81
Self-citationSARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar
Seedat, S., Chemaitelly, H., Ayoub, H. H., Makhoul, M., Mumtaz, G. R., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., Butt, A. A., Coyle, P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97606-8 · Cited by 63
Self-citation
Research works printed but not linked: 11
- Al Kuwari, 2020, Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February-18 April 2020, BMJ Open, 10, e040428, 10.1136/bmjopen-2020-040428 · DOI
- Al-Thani, 2020, Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar, medRxiv
- Jeremijenko, 2020, Evidence for and level of herd immunity against SARS-CoV-2 infection: the ten-community study, medRxiv
- Kellam, 2020, The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection, J Gen Virol, 101, 791, 10.1099/jgv.0.001439 · DOI · Paper page
- Kalikiri, 2020, High-throughput extraction of SARS-CoV-2 RNA from nasopharyngeal swabs using solid-phase reverse immobilization beads, medRxiv
- Kubina, 2020, Molecular and serological tests for COVID-19, a comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics, Diagnostics (Basel), 10
- Muench, 2020, Development and validation of the elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2, J Clin Microbiol, 58, 10.1128/JCM.01694-20 · DOI · Paper page
- Sethuraman, 2020, Interpreting diagnostic tests for SARS-CoV-2, JAMA, 323, 2249, 10.1001/jama.2020.8259 · DOI · Paper page
- Wajnberg, 2020, Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study, Lancet Microbe, 1, e283, 10.1016/S2666-5247(20)30120-8 · DOI · Paper page
- Grubaugh, 2020, Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear, Cell, 182, 794, 10.1016/j.cell.2020.06.040 · DOI · Paper page
- To, 2020, COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing, Clin Infect Dis
Cited by
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831
Self-citationFunctional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
Rodda, L. B., Netland, J., Shehata, L., Pruner, K. B., Morawski, P. A., Thouvenel, C. D., Takehara, K. K., Eggenberger, J., Hemann, E. A., Waterman, H. R., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.029 · Cited by 647
Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E. J. M., Simmons, R., Wellington, E., Cole, M. J., Saei, A., Oguti, B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00675-9 · Cited by 638
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
Altarawneh, H. N., Chemaitelly, H., Hasan, M. R., Ayoub, H. H., Qassim, S., AlMukdad, S., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Benslimane, F. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2200133 · Cited by 445
Self-citationImmunological characteristics govern the transition of COVID-19 to endemicity
Lavine, J. S., Bjornstad, O. N., & Antia, R. (2021) · Science · doi:10.1126/science.abe6522 · Cited by 416
Metadata
- Authors
- Abu-Raddad, L. J., Chemaitelly, H., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Ayoub, H. H., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., Butt, A. A., Coyle, P., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Yassine, H. M., Al Kuwari, M. G., Al Romaihi, H. E., Al-Thani, M. H., & Bertollini, R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-12-14
- Volume
- 73
- Issue
- 7
- Pages
- e1830-e1840
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3113150913
- Cited by
- 180
- References
- 9
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Biomedical Research Program; the Biostatistics, Epidemiology, and Biomathematics Research Core
- Genomics Core
- Weill Cornell Medicine–Qatar
- Ministry of Public Health
- Hamad Medical Corporation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. https://app.cochat.ai/papers/10.1093/cid/ciaa1846
- The paper
- Abu-Raddad, L. J., Chemaitelly, H., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Ayoub, H. H., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., Butt, A. A., Coyle, P., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Yassine, H. M., Al Kuwari, M. G., . . . Bertollini, R. (2021). Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1846
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.